Association of periodontitis with cognitive decline and its progression: Contribution of blood-based biomarkers of Alzheimer's disease to this relationship
- PMID: 37584311
 - DOI: 10.1111/jcpe.13861
 
Association of periodontitis with cognitive decline and its progression: Contribution of blood-based biomarkers of Alzheimer's disease to this relationship
Abstract
Aim: To assess whether periodontitis is associated with cognitive decline and its progression as well as with certain blood-based markers of Alzheimer's disease.
Materials and methods: Data from a 2-year follow-up prospective cohort study (n = 101) was analysed. Participants with a previous history of hypertension and aged ≥60 years were included in the analysis. All of them received a full-mouth periodontal examination and cognitive function assessments (Addenbrooke's Cognitive Examination (ACE) and Mini-Mental State Examination [MMSE]). Plasma levels of amyloid beta (Aβ)1-40 , Aβ1-42 , phosphorylated and total Tau (p-Tau and t-Tau) were determined at baseline, 12 and 24 months.
Results: Periodontitis was associated with poor cognitive performance (MMSE: β = -1.5 [0.6]) and progression of cognitive impairment (hazard ratio [HR] = 1.8; 95% confidence interval: 1.0-3.1). Subjects with periodontitis showed greater baseline levels of p-Tau (1.6 [0.7] vs. 1.2 [0.2] pg/mL, p < .001) and Aβ1-40 (242.1 [77.3] vs. 208.2 [73.8] pg/mL, p = .036) compared with those without periodontitis. Concentrations of the latter protein also increased over time only in the periodontitis group (p = .005).
Conclusions: Periodontitis is associated with cognitive decline and its progression in elderly patients with a previous history of hypertension. Overexpression of p-Tau and Aβ1-40 may play a role in this association.
Keywords: Tau protein; amyloid beta peptides; biomarkers; dementia; periodontitis.
© 2023 The Authors. Journal of Clinical Periodontology published by John Wiley & Sons Ltd.
References
REFERENCES
- 
    
- Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019). Diagnosis and management of dementia: Review. JAMA, 322(16), 1589-1599. https://doi.org/10.1001/jama.2019.4782
 
 - 
    
- Ashton, N. J., Hye, A., Rajkumar, A. P., Leuzy, A., Snowden, S., Suárez-Calvet, M., Karikari, T. K., Schöll, M., la Joie, R., Rabinovici, G. D., Höglund, K., Ballard, C., Hortobágyi, T., Svenningsson, P., Blennow, K., Zetterberg, H., & Aarsland, D. (2020). An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 16(5), 265-284. https://doi.org/10.1038/s41582-020-0348-0
 
 - 
    
- Bir, S. C., Khan, M. W., Javalkar, V., Toledo, E. G., & Kelley, R. E. (2021). Emerging concepts in vascular dementia: A review. Journal of Stroke and Cerebrovascular Diseases, 30(8), 105864. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105864
 
 - 
    
- de La Torre, J. C. (2004). Alzheimer's disease is a vasocognopathy: A new term to describe its nature. Neurological Research, 26(5), 517-524. https://doi.org/10.1179/016164104225016254
 
 - 
    
- Díaz-Zúñiga, J., More, J., Melgar-Rodríguez, S., Jiménez-Unión, M., Villalobos-Orchard, F., Muñoz-Manríquez, C., Monasterio, G., Valdés, J. L., Vernal, R., & Paula-Lima, A. (2020). Alzheimer's disease-like pathology triggered by Porphyromonas gingivalis in wild type rats is serotype dependent. Frontiers in Immunology, 11, 588036. https://doi.org/10.3389/fimmu.2020.588036
 
 
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
